213 related articles for article (PubMed ID: 23557845)
1. HbA1c targets in type 2 diabetes: guidelines and evidence.
Drug Ther Bull; 2013 Apr; 51(4):42-5. PubMed ID: 23557845
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
5. Metformin decreases glycated albumin to glycated haemoglobin ratio in patients with newly diagnosed type 2 diabetes.
Sumitani S; Morita S; Deguchi R; Hirai K; Mukai K; Utsu Y; Miki S; Sato B; Nakamura H; Kasayama S; Koga M
Ann Clin Biochem; 2015 Jan; 52(Pt 1):76-81. PubMed ID: 24604630
[TBL] [Abstract][Full Text] [Related]
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
7. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
9. Glucose control in diabetes: which target level to aim for?
Laakso M; Cederberg H
J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
[TBL] [Abstract][Full Text] [Related]
10. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
RodrÃguez-Gutiérrez R; Montori VM
Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
[TBL] [Abstract][Full Text] [Related]
11. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Zenari L; Marangoni A
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
Sharma M; Beckley N; Nazareth I; Petersen I
BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
[TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
14. Which patients should be evaluated for blood glucose variability?
Candido R
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():9-12. PubMed ID: 24034514
[TBL] [Abstract][Full Text] [Related]
15. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
16. Early and intensive treatment: Glycaemic control in type 2 diabetes.
Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):145-6. PubMed ID: 17160908
[No Abstract] [Full Text] [Related]
17. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
[TBL] [Abstract][Full Text] [Related]
18. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of type 2 diabetes: the evidence.
Colagiuri S
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():3-8. PubMed ID: 22118704
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
